Journal Watch · Nature Biotechnology · 2026

Directed evolution of small RNA-stabilizing motifs that improve prime-editing efficiency.

They also increased PE efficiencies for correcting disease-associated mutations in primary human cells and in vivo in mouse brain and liver.

Sakai HA, Pierce SE, Jiang AY et al.Nature Biotechnology3 min readPharma relevance 30/100

DOI: 10.1038/s41587-026-03123-2PMID: 42162366Study type: preclinical (animal / model) study

TL;DR

They also increased PE efficiencies for correcting disease-associated mutations in primary human cells and in vivo in mouse brain and liver.

Key findings

  • In a screen correcting 847 pathogenic ClinVar variants, the top-performing motifs improved PE efficiency over the widely used tevopreQ<sub>1</sub> motif for >90% of edits.
  • They also increased PE efficiencies for correcting disease-associated mutations in primary human cells and in vivo in mouse brain and liver.

Numbers at a glance (from the abstract)

90%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Here, using PE-PRISM, we evaluated 2,858 RNA motifs across four iterative libraries, including natural and engineered pseudoknots, G-quadruplexes and reverse transcriptase recruitment elements. We applied structure-guided mutagenesis and combinatorial variant screening to refine hits, culminating in the engineered and evolved pseudoknot variants tevo2.0, eHAV and eSBRMV1-A.

Full abstract (original)

Background: The performance of prime-editing (PE) systems has been improved by systematic engineering of their protein and small RNA components but the structured RNA motifs appended to the 3' end of PE guide RNAs (pegRNAs)-a key determinant of pegRNA stability and editing efficiency-have not been extensively studied. We introduce PE-PRISM, a high-throughput pooled screen to identify and optimize these 3' RNA motifs in human cells.

What they did: Here, using PE-PRISM, we evaluated 2,858 RNA motifs across four iterative libraries, including natural and engineered pseudoknots, G-quadruplexes and reverse transcriptase recruitment elements. We applied structure-guided mutagenesis and combinatorial variant screening to refine hits, culminating in the engineered and evolved pseudoknot variants tevo2.0, eHAV and eSBRMV1-A.

Results & conclusions: In a screen correcting 847 pathogenic ClinVar variants, the top-performing motifs improved PE efficiency over the widely used tevopreQ<sub>1</sub> motif for >90% of edits. They also increased PE efficiencies for correcting disease-associated mutations in primary human cells and in vivo in mouse brain and liver.

Abstract © the authors / Nature Biotechnology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41587-026-03123-2 · PubMed 42162366.

Why it matters for pharma & biotech

  • Relevant to Biology & Life Sciences teams tracking Nature Biotechnology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Nature Biotechnology study find?

They also increased PE efficiencies for correcting disease-associated mutations in primary human cells and in vivo in mouse brain and liver.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Biotechnology in 2026. Here, using PE-PRISM, we evaluated 2,858 RNA motifs across four iterative libraries, including natural and engineered pseudoknots, G-quadruplexes and reverse transcriptase recruitment elements.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41587-026-03123-2. PubMed ID: 42162366. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Sakai HA, Pierce SE, Jiang AY et al.. Directed evolution of small RNA-stabilizing motifs that improve prime-editing efficiency.. Nature Biotechnology (2026). DOI: 10.1038/s41587-026-03123-2.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/directed-evolution-of-small-rna-stabilizing-motifs-that-improve-prime-ed-031232/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides